glp-1 grocery news How food brands can win in the era Food companies are targeting users

46 That dedicated kidney outcomes study, involving over 3500 patients with both T2D and established chronic kidney disease, demonstrated that once-weekly subcutaneous semaglutide 1.0 mg significantly reduced the primary composite renal outcome (including kidney failure onset, a 50% persistent decline in estimated glomerular filtration rate (eGFR), or renal/cardiovascular death) compared with placebo

1):S6-S10 2

The results of Glutathione IV therapy may vary depending on the individual and their specific skin needs

Development of a cell transducible RhoA inhibitor TAT-C3 transferase and its encapsulation in biocompatible microspheres to promote survival and enhance regeneration of severed neurons

Transient redness or warmth at the injection site